Sobi submits biologics license application to the FDA for SEL-212, targeting chronic refractory gout treatment.

Tyra Biosciences has reported preclinical proof-of-concept findings for TYRA-300, an experimental orally administered FGFR3 selective inhibitor.

Satellos Reveals Initial Data Indicating Muscle Recovery and Healing from SAT-3247 Treatment in Dog Model of Duchenne Muscular Dystrophy (DMD).

The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.

KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.

Idorsia’s JERAYGO (aprocitentan) approved in Europe as the first and only ERA for resistant hypertension treatment.

TauRx Pharmaceuticals Ltd has revealed the filing of a Marketing Authorisation Application in the UK for hydromethylthionine mesylate (HMTM).

Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.

Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.

The European Union has approved the world's first Sanofi and Regenerant drug, dulprizumab, targeting IL-4Rα for COPD treatment.

Pierre Fabre Laboratories have received European marketing approval for OBGEMSA™ (vibegron) to treat overactive bladder.